Explore more about: COVID-19

A new study that could have immediate implications for COVID-19 testing in schools found that with age-appropriate instructions, school-aged children can successfully use a nasal swab to obtain their own COVID-19 test specimen.

Researchers funded by NIH's RADx Tech program have developed a fast, cost-effective method to detect the circulation of SARS-CoV-2 variants. The team adopted a customizable genotyping approach to identify known variants and subvariants—an approach that can augment current surveillance.

A new type of COVID-19 test is hitting the market, and could change how we detect the virus. MicroGEM, a Virginia-based molecular biology company with a Charlottesville office, is using its new saliva test to track COVID-19. Source: NBC TV12 Richmond, Virginia.

Two recent studies supported by the National Institutes of Health Rapid Acceleration of Diagnostics (RADx) Tech program demonstrate how widespread distribution of COVID-19 at-home antigen tests can be used as an effective public health strategy to reduce the spread of the disease. Source: UMass Chan

A new rapid PCR COVID-19 test invented by Northwestern University faculty and Minute Molecular Diagnostics has received FDA emergency use authorization.

A small preliminary study from Northwestern Medicine has shown that a blood test may identify risk of stillbirth and placentitis in pregnant individuals who have had COVID-19. The finding builds on another study with similar results and could have implications in how physicians screen for and address high-risk pregnancies.

RADx Tech program has issued contracts to help meet the ongoing needs and challenges of COVID-19 diagnostic testing.

The National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx®) Tech program is working to identify necessary elements of at-home COVID-19 diagnostic test kits that may be used independently by people with disabilities.

Siemens Healthineers AG will supply 50 million rapid Covid-19 test kits as part of President Joe Biden‘s push to deliver 1 billion free at-home tests to Americans, the Defense Department said.

Fluidigm, "the South San Francisco-based company, which landed NIH money in a Shark Tank-style program for Covid-19 testing, announced that it will take on an investment worth $250 million from Casdin Capital and Viking Global investors, ". The company "will also rebrand, and call itself Standard BioTools.